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Abstract
Heparin cofactor II (HCII) is a serine protease inhibitor (serpin) that has been shown to be a predictor
of decreased atherosclerosis in the elderly and protective against atherosclerosis in mice. HCII
inhibits thrombin in vitro and HCII-thrombin complexes have been detected in human plasma.
Moreover, the mechanism of protection against atherosclerosis in mice was determined to be the
inhibition of thrombin. Despite this evidence, the presence of HCII in human atherosclerotic tissue
has not been reported. In this study, using samples of coronary arteries obtained from the
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study, we explore the local
relationship between HCII and (pro)thrombin in atherosclerosis. We found that HCII and (pro)
thrombin are co-localized in the lipid-rich necrotic core of atheromas. A significant positive
correlation between each protein and the severity of the atherosclerotic lesion was present. These
results suggest that HCII is in a position to inhibit thrombin in atherosclerotic lesions where thrombin
can exert a proatherogenic inflammatory response. However, these results should be tempered by
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the additional findings from this, and other studies, that indicate the presence of other plasma proteins
(antithrombin, albumin, and α1-protease inhibitor) in the same localized region of the atheroma.
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INTRODUCTION
Heparin cofactor II (HCII) is a serine protease inhibitor (serpin) that has been strongly
implicated in the inhibition of atherosclerosis (Aihara et al., 2007; Aihara et al., 2004; Huang
et al., 2007; Tollefsen, 2007; Vicente et al., 2007). Individuals with high levels of HCII have
been shown to have less atherosclerosis than their counterparts (Aihara et al., 2004), and HCII
deficient mice show increased atherosclerotic plaque formation (Aihara et al., 2007; Vicente
et al., 2007). Thrombin exhibits mitogenic and chemotactic activities that contribute to the
chronic inflammatory processes of atherosclerosis (Baykal et al., 1995; Harker et al., 1995).
Studies that examined restenosis after arterial stent placement showed that elevated blood
concentrations of HCII were associated with decreased incidence of restenosis (Schillinger et
al., 2004; Takamori et al., 2004); the processes that dominate restenosis, smooth muscle cell
proliferation and migration, are also important processes in atherogenesis and can be induced
by thrombin. HCII-thrombin complexes have been detected in human plasma (Liu et al.,
1995) and, thrombin has been found in its active form in atherosclerotic lesions (Stoop et al.,
2000). HCII inhibits thrombin at physiologically relevant rates only in the presence of
glycosaminoglycans (GAGs) (Rau et al., 2007). Dermatan sulfate is the predominant
antithrombotic GAG in the artery wall (Tovar et al., 2005). It specifically accelerates HCII
inhibition of thrombin and has been shown to have decreased activity in atherosclerotic lesions
as compared to normal tissue (Shirk et al., 2000). Although HCII is presumed to regulate
thrombin in atherosclerosis, the presence of HCII in atherosclerotic lesions has not been
reported.
In this study we utilized atherosclerotic lesions of coronary arteries sampled from the
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research program. PDAY
was established in 1985 to quantitatively assess the risk factors for coronary heart disease. Data
and arterial samples from over 3,000 individuals from the ages of 15–34 who died of external
causes (accidents, homicides, suicides) were collected by fifteen cooperating centers across
the United States and managed by the Department of Pathology at Louisiana State University
Health Science Center. The data published using PDAY has greatly enhanced our
understanding of atherosclerosis and its associated risk factors (see (McGill et al., 2008) for
recent review).
We probed the atherosclerotic plaques for HCII, (pro)thrombin and several other proteins with
the hypothesis that we would find decreased levels of HCII and increased levels of thrombin
in more severe atherosclerotic plaques, reasoning that less HCII would result in decreased
thrombin inhibition and therefore more severe atheromas.
MATERIALS AND METHODS
Histological Samples
Samples of human left anterior descending (LAD) coronary artery were collected, formalin-
fixed, paraffin-embedded, serially sectioned and mounted on glass slides by PDAY (Cornhill
et al., 1995; Strong et al., 1999; Strong et al., 1997; Wissler, 1994). Twenty-eight cases with
varying severity of atherosclerotic lesions were analyzed in this study.
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Sections of formalin-fixed, paraffin-embedded liver were obtained from the McLendon
Clinical Laboratory at the University of North Carolina Hospitals, cut into 4 µm serial sections
and mounted on glass slides. These served as positive controls slides for immunohistological
staining as almost all of the proteins that were probed are of hepatic origin. The exception is
maspin, a non-plasma serpin of mamillary epithelial origin involved in tumor suppression.
Maspin is not synthesized in the liver and thus served as a negative control. A liver section
with a maspin-positive tumor served as the maspin-positive control.
Slide Preparation, Mounting and Staining with Hematoxylin and Eosin
Before staining, paraffin was dissolved and slides were rehydrated using standard techniques.
After staining and dehydration all slides were coverslipped using 1 drop of Permount Mounting
Media (Fisher Scientific) and air dried overnight. For staining with hematoxylin and eosin,
rehydrated slides were immersed first for eight minutes in filtered Mayer’s hematoxylin
(Dako), rinsed in tap water until no more dye was evident and then soaked in tap water for 10
minutes. Slides were then rinsed in distilled and deionized water before being dipped ten times
in 95% ethanol. Slides were then submersed for 45 seconds in Eosin Y (Sigma) followed by
95% ethanol for five more minutes.
Antigen Retrieval
Heat-induced antigen retrieval was employed for probing the AT antigen only. Six slides at a
time were placed into plastic Copeland jars with a large hold drilled in the lid filled with Tissue
Unmasking Fluid (Invitrogen). These jars were placed into 400 mL glass beaker in 180 mL of
distilled, deionized water and heated on highest power in a Samsung Classic Collection
Microcooking microwave for 2.5 minutes. The water was then exchanged for 180 mL of fresh
water and the beaker containing the Copeland jar with slides was heated again on highest power
for 2.5 minutes to bring the internal temperature to 90° C. The water was exchanged again for
180 mL of tap water and everything was permitted to cool for 20 minutes.
Immunohistochemical Staining
Slides were laid flat on a rack and incubated in 460 µL per slide of each successive solution.
To remove solution, slides were rinsed with Dulbecco’s phosphate buffered saline (PBS)
(Gibco) containing 1% Tween 20 (Sigma) (PBStw1%). Before and between incubation with
each solution, slides were washed in PBStw1% for three minutes. First, endogenous peroxidase
activity was blocked with either HRP-Block (Dako) for five minutes or with 3% hydrogen
peroxide for ten minutes. Slides were then incubated for one hour in the dark with primary
antibody diluted in PBS with either 1% ovalbumin or 1% bovine serum albumin. Table 1
describes the antibodies used, their dilutions and incubation times. Next, slides were incubated
in the dark with peroxidase conjugated secondary antibody appropriately matched to primary
antibody either HRP-conjugated donkey anti-goat IgG (Serotec) or HRP labeled polymer
(Dako). Secondary antibodies were diluted in the same solution as their primary antibodies.
Slides were then covered with nine drops per slide of diaminobenzidine solution (DAB)
(DAKO) and let sit for eight minutes. DAB staining was enhanced using a solution of 2.5%
cobalt chloride, 2.5% nickel ammonium sulfate for eight minutes and rinsed in water. Slides
were counterstained for five minutes with Mayer’s Hematoxylin (Dako or Sigma), rinsed in
tap water for five minutes before dehydrating and coverslipping.
Lesion Classification
One serial section from each case was stained with hematoxylin and eosin. Using this slide set,
the severity of each atherosclerotic lesion was classified separately by three trained individuals.
Plaque severity was rated from I (least severe) to VI (complicated lesions) according to the
American Heart Association classification system (Stary et al., 1995; Stary et al., 1994).
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The intensity of staining for each probed antigen was also independently ranked on a scale of
0 to 3 with 0 indicating no staining, 1 indicating weak staining, 2 indicating intermediate
staining and 3 indicating strong staining. Raters were unaware of the specific antigen probed
when they were rating staining intensity. Additionally, raters were asked to consider staining
intensity only in the tunica intima and tunica media as these are the portions of the vessel
susceptible to atherosclerosis. Images were created using the Aperio ScanScope and Aperio
ImageScope software version 9.0. Slides were scanned using factory settings for
immunohistochemistry.
Statistical Analysis
Mean scores for lesion severity and staining intensity were computed for each slide. Spearman
correlation coefficients, with their corresponding p-values, were computed to evaluate the
correlation between the mean scores for each of the probed proteins and severity of the
atherosclerotic lesions. The mean score for each protein decreased the variance of scores,
thereby increasing the power for detecting a significant correlation when it did exist. The use
of the mean scores had support from assessment of intra-rater reliability with intra-class
correlations. In order to maintain an overall type 1 error rate of 0.05 throughout five
comparisons between lesion severity and staining intensity, there was adjustment for multiple
comparisons with the Bonferroni-Holm method; i.e., the smallest p-value was initially
compared to 0.05/5=0.01, if significant, then the second-smallest p-value was compared to
0.05/4=0.0125. If significant, the third-smallest p-value was compared to 0.05/3=0.01667, and
so on for each of the five p-values, stopping when a non-significant result was observed.
RESULTS
Ratings of Lesion Severity and Antigen Staining of LAD Coronary Artery Sections
Atherosclerotic lesions were categorized from 1 to 5. No category 6 lesions were observed.
Staining of each of the circulating proteins (HCII, (pro)thrombin, AT, albumin, and α1-protease
inhibitor) was observed with intensity range of 0 to 3. Staining intensity for maspin as rated 0
by all reviewers for every section where it was probed despite strong staining on its positive
control (tumor in the liver – data not shown). Assessment of inter-rater reliability by inter-class
correlation coefficients (ICCs) results in ICCs above 0.5 (Table 2), indicating that there is
reliability among raters. This supports the use of the mean scores to assess correlations between
plaque severity and staining intensity.
Each of the plasma proteins probed was detected in atheromatous lesions. Maspin was not
found in any vessels. Antigen staining was primarily in the lipid rich, necrotic core of the
atheromas. Figure 1 shows an example of serial sections of one sample of LAD atherosclerotic
coronary artery, immunoprobed for each circulating protein. This atheroma was rated with an
average lesion severity of 4.67. Mean staining intensity for the particular atheroma shown in
Figure 1 was HCII = 3.00, AT = 1.67, (pro)thrombin = 3.00, α1-protease inhibitor = 3.00,
albumin = 3.00 and goat IgG = 0.
It is evident from Figure 1 that there is protein from all of the circulating proteins found in this
atheromatous sample. There is some detectable HCII, AT and albumin in the endothelial region,
but not the other proteins. It is of value to note the paucity of staining in the less atherosclerotic/
more normal portion of the vessel (seen in the right-most column in Figure 1). No antigen
staining was detected in the normal non-atherosclerotic intimal region of this or any of the
LAD coronary arteries used in this study. This atheroma represented the pattern of distribution
of all of the LAD samples, with staining present predominantly in atherosclerotic core regions
and little to no staining perceivable in non-atherosclerotic tunic intima or tunica media.
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Relationship Between Plaque Severity and Antigen Staining
Spearman correlation coefficients were determined to evaluate the correlation between lesion
severity and staining intensity, using the Bonferroni Holm method to adjust for multiple
comparisons. This analysis indicates that HCII staining, (pro)thrombin staining, and AT
staining were significantly positively correlated with lesion severity (Table 3). The relationship
between plaque severity and (pro)thrombin was the strongest with its Spearman’s coefficient
= 0.81, that for HCII = 0.63 and for AT = 0.48 (Table 3). α1-Protease inhibitor and albumin
did not appear to be correlated with lesion severity (Table 4), although only the most severe
slides were available to be rated for these proteins, thus limiting our ability to detect a
correlation with lesion severity for these proteins if one does exist.
DISCUSSION
When beginning the quest to detect the localization of HCII and thrombin in atherosclerotic
plaques, we hypothesized that in more severe atherosclerotic plaques there would be low
concentrations of detectable HCII and high concentrations of thrombin as compared with less
severe atheroscleromas. Somewhat at odds with this hypothesis, we detected more HCII in the
more severe atherosclerotic lesions as evidenced by a statistically significant positive Spearman
Correlation (Table 3). However, as predicted (pro)thrombin staining exhibited a positive
correlation between intensity and lesion severity. Both HCII and (pro)thrombin were detected
in the same lipid-rich regions and necrotic cores of the atheromas. One explanation includes
that more thrombin present in severe atheromas drives a more severe atherosclerotic process
but also provides more ligand for HCII to bind. To effectively inhibit thrombin, a GAG cofactor
is necessary. Dermatan sulfate is the predominant GAG in the arterial wall (Tovar et al.,
2005) and is specific for HCII. Furthermore, it has been shown that dermatan sulfate found in
atheromas has decreased ability to accelerate HCII inhibition of thrombin (Shirk et al., 1996).
Therefore, although there is more HCII in severe plaques than compared to less severe plaques,
its ability to inhibit thrombin in this arena may be restricted and thus a more severe plaque is
evidenced.
The studies that the inhibition thrombin by HCII in atherosclerosis, also indicate that AT, the
prominent thrombin inhibitor in coagulation, is unable to fulfill this role (Aihara et al., 2007;
Vicente et al., 2007). Therefore, to substantiate the functional specificity of HCII in the
atheromas, we probed adjacent sections for the presence of AT, expecting to find little there.
To our surprise, AT was detected in the atheromas, in the same location as HCII and (pro)
thrombin. The AT staining was somewhat less intense across all of the arterial samples despite
comparable staining intensity to HCII and (pro)thrombin in the liver positive controls (data not
shown). Due to variability in the quality of antibodies and the requirement to use heat-induction
for antigen retrieval for AT, it is irresponsible to compare relative protein concentrations for
different proteins in these stained vessels. So while the data hints of less AT than HCII in the
atheroma, this cannot be firmly established under these conditions. The results do however
demonstrate a positive correlation between staining intensity of AT and plaque severity, albeit
not as strong as for (pro)thrombin or HCII. This suggested to us that perhaps the HCII and
(pro)thrombin co-localization in the lipid-rich core of the atheromas might not be as specific
as we had anticipated.
To further investigate the specificity of the co-localization of these thrombin-inhibiting serpins
and (pro)thrombin, we probed additional adjacent LAD coronary artery sections for a non-
thrombin-inhibiting plasma serpin, α1-protease inhibitor (α1PI); a non-serpin plasma protein,
albumin; and a non-circulating serpin, maspin. Although we can find no evidence establishing
a role for α1PI or albumin in the pathophysiology of atherosclerosis, both of these proteins
were found localized in the same region as HCII, (pro)thrombin, and AT (Figure 1). While
correlations between staining intensity and plaque severity were not significant with albumin
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and α1PI, this could be due to the smaller number of slides probed. It is perhaps more important
that these proteins are found in the atheromas while maspin, which is similarly sized and is
from the same family, but is not a circulating protein, was not detected.
In an attempt to determine if the (pro)thrombin in atherosclerotic lesions was thrombin or
prothrombin and if it was complexed with either the HCII or AT, we examined homogenized
aorta by immunoblot analysis (data not shown). Results from these experiments confirmed the
presence of HCII, AT, thrombin and prothrombin in atherosclerotic tissue and also in normal
vessel. We did not observe thrombin-serpin complexes in either normal or atherosclerotic
homogenized aorta. These results do not eliminate the possibility or even probability that
thrombin is inhibited by HCII in the atherosclerotic vessel. It is very likely that serpin-thrombin
complexes are cleared more quickly from the vessel microenvironment, or that they are
somehow less detectable to the antibodies used here.
The presence in atherosclerotic lesions of all of the circulating proteins probed for in this study,
but not the non-circulating serpin, maspin, suggests severe atherosclerotic lesions may act as
a mire for plasma proteins and that the co-localization of proteins in this region may be non-
specific. The positive correlation with plaque severity for HCII, (pro)thrombin and AT bolster
this theory especially since the endothelium is known to show increased permeability with
atherosclerosis (Feletou and Vanhoutte, 2006; Hirano, 2007; Simionescu, 2007). As the barrier
function of the endothelium deteriorates, plasma components are more able to filter into the
plaque and become trapped in the fatty debris laden region of atheromas. Many other circulating
proteins, in addition to those reported here, have been found in the identical region of human
atherosclerotic lesions including the apolipoproteins, apoA-I, apoB and apoE (O'Brien et al.,
1998; Wyler von Ballmoos et al., 2006), C-reactive protein (Sun et al., 2005), vonWillebrand
factor (Sun et al., 2005), and resistin (Burnett et al., 2005). Sound explanations for the existence
and retention of these proteins in atherosclerotic plaques have been presented, just as there
appears to be good reason for the presence of thrombin and HCII. One could even make a case
for the retention of albumin in the plaque as it is known to bind fatty acids. However, we are
unable to rationalize the function of α1-protease inhibitor in the atheroma. This is not to say
that none of the proteins found in atherosclerotic lesions influence its progression. Contrarily,
we find it likely that many of these proteins play a role in atherosclerotic regulation or
advancement. For example, fibrin has been found in atherosclerotic plaques (Kaikita et al.,
1999). While it is possible that it had been deposited by infiltrating macrophages, it is just as
likely that all of the necessary coagulation factors leak into the plaque and are activated by the
presence of tissue factor bearing cells in the atheroma. The result would be fibrin in the
atherosclerotic plaque that does not resemble a typical fibrin clot because platelets and red
blood cells would be absent from the milieu. This hypothesis also explains how thrombin could
be detected in its active form in atherosclerotic plaques. Thus the increased permeability of
atherosclerotic lesions may actually be a thrombogenic factor in and of itself. This would
explain how increased serum HCII protects against atherosclerosis: as serum levels of HCII
increase, more HCII crosses into the intimal layer of a vessel with a increased endothelial
permeability and is able to neutralize thrombin that has also crossed the endothelium.
Our study also emphasizes a caveat that must be regarded in immunohistochemical
examinations of atherosclerosis. While the presence or co-localization of any circulating
protein(s) in atherosclerotic lesion may have functionality, it is important to consider that
proteins found in the acellular, lipid-rich region of an atheroma, may simply be the result of
increased endothelial permeability and may or may not contribute to atherogenesis and to its
regulation.
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In this study, we asked is HCII present in atherosclerotic lesions, does it co-localize with
thrombin and is there a relationship between these proteins and the severity of the
atherosclerosis? The results of immunohistochemical and immunoblot analyses establish the
co-localization of (pro)thrombin with HCII in the core of atherosclerotic plaques and
demonstrates a positive correlation between the presence of HCII, (pro)thrombin or
antithrombin (AT) and lesion severity. Additionally, these results indicate that atheromas may
act as a non-specific watershed for plasma proteins and should serve as a warning against
assumptions that co-localization of protein in atheromas implies a pathophysiologic role in
atherosclerosis.
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Figure 1. H&E and immunological staining of an example of a left, anterior descending coronary
artery with atherosclerotic lesion for various plasma proteins and goat IgG negative control
The left-most column shows a 1× view of the vessel, the middle column shows a 5× view of
the atheromatous lipid core and the right-most column a 5× view of the non-diseased region
with no visible atherosclerosis.
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Table 2
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Table 4
Breakdown of Tests of Significance Using Bonferroni-Holm Method to Adjust for Multiple Comparisons
Step Variable Observed p-valueCompare to Significant?
1 (Pro)thrombin <0.0001 0.01 YES
2 HCII 0.0003 0.0125 YES
3 AT 0.0090 0.01667 YES
4 Albumin 0.1918 0.025 NO → Stop after this step.
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